28th International Conference on
CANCER RESEARCH AND ANTICANCER THERAPIES
International Conference on &
ONCOGENESIS & ONCOLOGIC EMERGENCY MEDICINE
3rd International Conference on &
TUMOR & CANCER IMMUNOLOGY AND IMMUNOTHERAPY
September 17-18, 2018 | San Diego, USA

Indole-3-ethylsulfamoylphenylacrylamides with Potent Anti- proliferative and Anti-angiogenic Activities

Jing-Ping Liou[1], Samir Mehndiratta[1], Shiow-Lin Pan[1], Sunil Kumar[2], Chia-Ron Yangc and **Jing-Ping Liou[1]**
[1]Taipei Medical University, Taiwan
[2]National Taiwan University, Taiwan

Histone deacetylases (HDACs) display multifaceted functions by coordinating the interaction of signal pathways with chromatin structure remodeling and thus play an important role during malignancy progression. HDAC inhibition shows promise as a new strategy for cancer therapy and four HDAC inhibitors have been approved. We have synthesized a PXD101-LBH589 core model based series of potent indole-3-ethyl sulfomoylphenylacrylamides as potent inhibitors of HDACs, developed the SAR and evaluated them for their anti-cancer and anti-angiogenic effects.

Biography

Samir Mehndiratta is a postdoctoral research fellow in Department of Medicinal Chemistry at Taipei Medical University (TMU), Taiwan. He has his expertise in small molecules as potent anticancer compounds and his work accentuates on designing and synthesizing inhibitors of various epigenetic modulations like HDAC inhibitors, HAT Inhibitors, target based therapy, designed multiple ligand (DML) based drug design and personalized medicines for the treatment of cancer. During his doctorate, he received QS-Apple Scholarship 2014 for outstanding research and social engagements. With high impact papers in various research journals he has been awarded with Outstanding Postdoctoral Award for year 2016 and 2017 from TMU and has also received Young Research Scientist Award 2018 from SBMLS (India).

sam131301@yahoo.co.in

Notes: